At Innogene Kalbiotech we enrich diagnostics, therapeutics and health care by bringing in the latest breakthroughs in biology and biotechnology. Our products carry forward our mission to transforms patients’ health and lives, which we believe will work towards bettering life globally.

One of our diagnostic products is MammaPrint, which in 2007 was the first FDA cleared IVDMIA breast cancer recurrence assay. MammaPrint has a unique 70-gene signature that provides unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.

Another product is the Tumor M2-PK Stool Test, a highly sensitive and specific metabolic biomarker for colorectal cancer screening, which is independent of "Faecal Occult Blood" (FOB).